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ABSTRACT
Poly(ADP-ribose) polymerase-1 (PARP-1) has been
involved in endothelial cell dysfunction associated
with various pathophysiological conditions. The
intrinsic mechanism of PARP-1-mediated endothe-
lial cell dysfunction could be related to PARP-1
overactivation, NAD+ consumption and ATP deple-
tion. An alternative way could involve transcription
regulation. By using high-density microarrays, we
examined early tumor necrosis factor a (TNF-a)-
stimulated gene expression pro®les in PARP-1+/+
and PARP-1±/± murine heart endothelial cells. TNF-a
modulated a signi®cant number of genes in both
cell types. We have identi®ed a set of genes whose
expression in response to TNF-a is modulated by
PARP-1, whereas the expression of others is PARP-
1-independent. Up-regulation of several genes
involved in the in¯ammatory response is hampered
in the absence of PARP-1. Moreover, NF-kB-depend-
ent transcriptional activation is partially inhibited in
PARP-1±/± compared to PARP-1+/+ cells. However, we
found that PARP-1 might also silence transcription
of several NF-kB target genes. Overall, our results
show that PARP-1 is regulating the expression of
genes by the endothelial cells both in a positive and
a negative fashion, with the ®nal effects depending
on the gene. Individual studies of these genes are
now necessary to clarify the intrinsic mechanism by
which PARP-1 is controlling transcription and
thereby ®nding out different therapeutic approaches
involving PARP-1.
INTRODUCTION
Endothelial cell dysfunction is an important early-recurring
phenomenon in virtually all forms of ischemia and reperfusion
injury (1,2) and plays a critical role in uncontrolled in¯am-
matory conditions such as sepsis and multiorgan dysfunction
syndrome (3). Pro-in¯ammatory mediators released following
insult initiate signaling pathways to the nucleus in the
endothelial cells, mediated by NF-kB and other stress-
responsive transcription factors which reprogram gene expres-
sion (4). The overall result is a dysregulation of endothelial
function, leading to ¯uid leakage, transmigration of leuko-
cytes across the endothelium, thrombosis, end organ damage,
multiple organ dysfunction and often death (5). The cytokine
tumor necrosis factor a (TNF-a) is one of the most important
mediators of the in¯ammatory process, and a large number of
genes have been identi®ed that are responsive to TNF-a (6).
Such genes include cytokines, transcription factors, adhesion
molecules and structural proteins. TNF-a-dependent gene
expression is mainly mediated by the transcription factor
NF-kB. Under basal conditions, NF-kB is found in an inactive
cytoplasmic form bound to the inhibitor IkB (7). Upon TNF-a
signaling, IkB undergoes post-translational modi®cation
(phosphorylation and polyubiquitination) that leads to its
degradation and dissociation from NF-kB. The released
NF-kB is then translocated to the nucleus where it activates
the transcription of genes carrying NF-kB binding sites in their
promoters.
Recent evidence suggests that the enzyme poly(ADP-
ribose) polymerase 1 (PARP-1) is involved in the endothelial
dysfunction observed in various pathophysiological condi-
tions such as reperfusion (8), endotoxic shock (9), diabetes
(10) and aging (11). PARP-1 (EC 2.4.2.30) is a highly
conserved nuclear zinc-®nger DNA-binding protein (113 kDa).
PARP-1 speci®cally detects DNA-strand breaks or nicks
generated by different genotoxic agents (12) and, using NAD+
as a substrate, synthesizes and transfers ADP-ribose onto
glutamic acid residues of acceptor proteins, including itself
(automodi®cation), histones, transcription factors and DNA
repair proteins (13). In addition, it has been suggested that
signals other than DNA lesions, including steroid hormones,
stress and infection, may also activate PARP molecules at
speci®c chromosome sites (14). Despite intense recent interest
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in the biochemical properties and signaling function of PARP-
1, its physiological function remains under debate.
An important tool for the analysis of this issue has been the
development of PARP-1 knockout mice (PARP-1±/±) (15±17).
Although PARP-1-de®cient mice are viable, they accumulate
chromosomal abnormalities and are defective in DNA damage
repair. Moreover, PARP-1±/± mice are protected against a
variety of experimentally induced disorders with a clear
in¯ammatory component (18). The underlying mechanism of
endothelial cell dysfunction mediated by PARP-1 could be
attributed to PARP-1 overactivation, with resulting NAD+
consumption and ATP depletion (10,19). However, an alter-
native way in which PARP-1 may in¯uence endothelial cell
function could be through its transcription regulation function
(20,21). Thus, it has been demonstrated that PARP-1 is
necessary for the induction of NF-kB-dependent gene expres-
sion after exposure to LPS, TNF-a or hydrogen peroxide
(22,23). However, since translocation of NF-kB to the nucleus
occurred in PARP-1±/± cells as it did in the wild-type (23), a
new level of control of NF-kB must occur after its trans-
location to the nucleus, in which PARP-1 seems to play a
crucial role (24). Hassa et al. (25) have suggested that PARP-1
is an essential and novel transcription coactivator for kB-
dependent gene expression. Recently, it has also been shown
that PARP-1 is required for the activation of other in¯amma-
tion-related transcription factors such as AP-1, SP-1, Oct-1,
YY-1 and STAT-1 (26,27). Thus, a large body of evidence has
implicated PARP-1 in the regulation of transcriptional activity
of eukaryotic genes (21). Indeed, PARP-1 might play a critical
role as a signaling molecule, which controls the expression of
multiple genes involved in the in¯ammatory response (18).
In the present study we use oligonucleotide microarrays
analysis to elucidate the role of PARP-1 in the early gene
expression of endothelial cell in response to TNF-a. This
approach allows a comprehensive analysis of global gene
expression in both PARP-1+/+ and PARP-1±/± cells under
different activation conditions. Our results show that the
expression of some genes by endothelial cells in response to
TNF-a is modulated by PARP-1 in both a positive and a
negative fashion, whereas the expression of other genes is
PARP-1-independent. Likewise, the expression of several NF-
kB-dependent genes is dramatically inhibited in the absence of
PARP-1 while the expression of other NF-kB-dependent
genes is up-regulated in PARP-1-de®cient cells suggesting
multiple regulatory processes that should be studied in an
individual way.
MATERIALS AND METHODS
Antibodies and chemicals
The following monoclonal antibodies were used: rat anti-
mouse CD102 (3C4), CD31 (MEC 13.3), CD105 (MJ7/18),
CD62E (10E9.6), CD106 (MVCAM.A) and CD54 (3E2), all
from BD Pharmingen (San Diego, CA). Fluorescein isothio-
cyanate-conjugated goat anti-rat IgG (H+L) antibody from
Caltag (Burlingame, CA). Horseradish peroxidase-conjugated
goat anti-rat IgG from Sigma (St Louis, MO). Proteasome
inhibitor MG-132 (Z-Leu-Leu-Leu-al) was purchased from
Sigma.
Cell isolation and culture
Murine heart endothelial cells (MHEC) were isolated from
female PARP-1 knockout (PARP-1±/±) and their wild-type
(PARP-1+/+) littermates (strain 129/Sv X C57BL/6) mice (9±
10 weeks old) (kindly provided by Dr de Murcia, Strasbourg,
France) (16), by collagenase treatment and cell sorting of
ICAM2-positive cells. Brie¯y, the hearts were washed
extensively with cold phosphate-buffered saline (PBS)
(Biowhittaker, Verviers, Belgium). Diced tissue was incu-
bated in PBS supplemented with 0.5 mg/ml of collagenase
(Boehringer, Mannheim, Germany) for 1 h at 37°C. After
washing twice in PBS, cells were incubated for a further
10 min in 0.25% trypsin/0.04% EDTA solution (Life
Technologies, Inc., Grand Island, NY), washed twice in PBS
supplement with 2.5% heat inactivated fetal calf serum (FCS)
(Life Technologies), and incubated for 30 min at 4°C with a
rat anti-mouse CD31 and a rat anti-mouse CD102 monoclonal
antibodies. After washing twice with cold PBS, cells were
incubated with sheep anti-rat Ig-conjugated microbeads (107
beads/ml) (Dynal, Oslo, Norway) for 15 min at 4°C. The
magnetically labeled cells were collected with a Dynal
magnetic particle concentrator. Positively selected cells
attached to the Dynabeads were washed ®ve times in PBS.
After detachment, cells were resuspended in RPMI 1640
medium (Life Technologies) supplemented with 20% FCS,
2 mM L-glutamine (Life Technologies), 1% penicillin/strepto-
mycin (Life Technologies), 1 mM sodium pyruvate (Sigma),
20 mM HEPES (Sigma), 1% non-essential amino acids
(Sigma), 50 mM 2-mercaptoethanol (Sigma), 100 mg/ml
endothelial cell growth supplement (Beckton Dickinson,
Mountain View, CA), 12 U/ml heparin (Rovi Laboratories,
Madrid, Spain) and plated onto ¯asks coated with gelatin
(100 mg/ml) (Sigma). Cells were split upon con¯uence by
tripsinization (0.25% trypsin/0.04% EDTA), washed and
incubated with rat anti-mouse CD102 mAb for 30 min at
4°C. After washing twice with cold PBS, cells were incubated
in the same buffer containing ¯uorescein-conjugated goat
anti-rat IgG (H+L) antibody. Following 30 min incubation at
4°C in the dark, the samples were again washed twice with
cold PBS, and resuspended in 500 ml of RPMI 1640 medium.
Positive cells were collected by ¯uorescence activated cell
sorting (FACS) using a MoFloâ cell sorter (Cytomation Inc.,
Fort Collins, CO) equipped with an Argon-ion blue laser
(excitation 488 nm) and a Red Diode Laser (excitation
635 nm). Forward and side light scatter and speci®c ¯uores-
cence were used to establish sort regions by using SummitTM
software (Cytomation) in a 1±2 drop single cell mode. Cells
were plated, and subcultured as described above. In all cases,
>99% of the cells stained positively for cell surface CD102,
displayed typical cobblestone morphology and were positive
for other typical endothelial cell markers as CD105, CD31,
CD54 and CD106 by ¯ow cytometry analysis in a FACS
cyto¯uorimeter (Becton Dickinson) using Cell Quest software
(Becton Dickinson) (data not shown).
Microarray
Primary MHECs derived from PARP-1+/+ and PARP-1±/± mice
were grown under identical conditions to 80±90% con¯uency.
After treatment with murine recombinant TNF-a (20 ng/ml)
(Sigma) for 2 h, total RNA was isolated from cells by using a
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Rneasy Total RNA Isolation kit (Qiagen, Valencia, CA)
following the manufacturer's instructions. Total RNA (8 mg)
was subjected to reverse transcription with Superscript (Life
Technologies), using a T77-(dT)24 primer containing a T7
RNA polymerase promoter site. Biotinylated complementary
RNA was made from 1 mg of cDNA and then fragmented to
~50±100 nt, following Affymetrix's instructions. Fifteen
micrograms of the in vitro transcripts with appropriate
controls and spikes were hybridized for 16 h at 45°C with
constant rotation at 60 r.p.m. to an Affymetrix U74Av2
microarray (Affymetrix, Santa Clara, CA), which contain
probes for 12 488 known genes and expressed sequences tags
(EST). Chips were washed and stained by using the EukGE-
WS2v4 protocol on an Affymetrix ¯uidics station. The stain
included streptavidin±phycoerythrin (10 mg/ml) (Molecular
Probes, Eugene, OR) and biotinylated goat anti-streptavidin
(3 mg/ml) (Vector Laboratories, Burlingame, CA). Chips were
scanned with Agilent Gene Array Scanner and visualized and
analyzed using Affymetrix software (Affymetrix Microarray
Suite 5.0; Affymetrix Data Mining Tool 3.0; Affymetrix
MicroDB 3.0). Expression values of transcripts were normal-
ized, according to the total intensity on the chip. Only those
differences in RNA abundance that were reproducible in
independent experiments with different batches of cells and
represented a change of 2-fold or greater were considered.
Quantitative RT±PCR
Total RNA was prepared from resting or stimulated MHEC
using Rneasy Total RNA Isolation kit. cDNA was synthesized
using oligo-(dT)16 primer and the GeneAmp RNA-PCR kit
(Roche, Foster City, CA). Quantitative real-time PCR was
performed in a Light-Cycler (Roche) using a Light Cycler-
FastStart DNA Master SYBR Green I kit (Roche). Speci®c
primers to the different genes analyzed are listed in Table 1. A
threshold was set in the linear part of the ampli®cation curve
(¯uorescence = f[cycle number]), and the number of cycles
needed to reach it was calculated for every gene. Melting
curves and agarose gel electrophoresis established the purity
of the ampli®ed band. Each gene was normalized to the
housekeeping gene b-actin before fold change was calculated.
Results are expressed as the relative fold increase or decrease
of the stimulated over the resting cells.
Transient transfection and luciferase activity
For transient-transfection experiments, MHEC were plated
into 24-well plates (2 3 104 cells/well) the day before
transfection. Cells were transfected by the liposome-mediated
gene transfer method as previously described (28). Brie¯y,
1.5 ml of Lipofectamine (Life Technologies) was mixed in
48.5 ml of Opti-MEM 1 (Life Technologies) with 0.475 mg of
a ®re¯y luciferase reporter plasmid under the control of a
3 3 kB consensus site from the HIV enhancer (29) or the
®re¯y luciferase pGL3-Control vector (Promega, Madison,
WI), and 0.025 mg (ratio 20:1) of the Renilla luciferase
expression vector pRLCMV (Promega) as an internal control
to normalize the values obtained with the ®re¯y luciferase
construct. Mixture was incubated for 30 min at room
temperature to allow the formation of DNA±lipid complexes.
The mixture was then diluted in 200 ml of Opti-MEM 1 and
added to the cell cultures. After 6 h in culture, 1 ml of growth
medium was added to the transfection mixture. Next day,
medium was replaced by a fresh one. Cells were cultured for
72 h, and lysed with passive lysis buffer (Promega). Fire¯y
and Renilla luciferase activity was measured by using the Dual
luciferase assay kit (Promega), as speci®ed by the manufac-
turer, to discriminate the activity of the two types of
luciferases, in a Optocomp I luminometer (MGM
Instruments, Inc., Hamden, CT).
ELISA
To determine the amount of secreted chemokines, cells
were seeded in 96-well plates at subclon¯uent density
overnight. The enzyme-linked immunosorbent assays
(ELISA) for MIP-2 and Cxcl10 were carried out using
supernatants according to the manufacturer's protocol
(Quantikineâ mouse MIP-2 and Cxcl10 immunoassay,
R&D Systems, Minneapolis, MN). Ccl7 production was
measured by a sandwich ELISA in which 500 ng of goat
polyclonal antibody to mouse Ccl7 (Abcam, Cambridge, UK)
was coated into a microtiter plate overnight at 4°C. The plates
were blocked with PBS containing 1% bovine serum albumin
Table 1. Primer sets used for quantitative real-time PCR analysis
Gene Forward primer Reverse primer
Cxcl2 TATCGATTCGCTAATTCACTG AAATGATGTGAACATGCACAC
Cxcl1 TGCTAAAAGGTGTCCCCAAG GCAGAACTGAACTACCATCG
Cxcl5 TCATGCAGAAACCTGTGTAG ATACGTAGTGGCCCAAATAG
Ccl7 CAAAGAAGGGCATGGAAGTCTG ATCCCTTAGGACCGTGATCAAC
Ccl5 TGAAGATCTCTGCAGCTGCCC GATTGGAGCACTTGCTGCTGG
Cx3cl1 AGTGACTGCTGAAGCAAGGAGC TCGACAAAGGGTTGGCTTCCTC
Cxcl10 AGTTCTAAGTTTACCTGAGCTC ACAAGTTCTTCCATATACAATGC
Tnfaip3 CTGCATGTATTTTGGGACTCC ATGGAATCTCTGGTTCTGAGC
Gadd45b GTTCAGAAGATGCAGGCGGTG AGCAGAACGACTGGATCAGGG
Slfn2 GGAAAATGCAAAGGCTGCTGGG GATTGCTCCACCTCCCGAATTC
Areg CCACATCCCCAGCGGTTCCAG GGATCCAGACAGACCTCCTTC
Csf2 CAACTCCGGAAACGGACTGTG GCTGTGCCACATCTCTTGGTC
Itga5 AGGAAGTCTGCAGCTAAGAGC GGTCTGGCTCCATTCTCTTTC
Gem CTCACTGCATACTTATATCCC AGCTCCTAAGTCTACAATCTC
Actin TCCCTGGAGAAGAGCTACGA AGGAAGGAAGGCTGGAAGAG
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(BSA) for 1 h at 22°C. Then, cell-free supernatants from
untreated or TNF-a-treated endothelial cells were added and
incubated for 1 h at 22°C. After washing, biotinylated goat
polyclonal antibody to mouse Ccl7 (R&D Systems) was added
for 1 h at 22°C. For developing the ELISA, after washing,
horseradish peroxidase-conjugated streptavidin (Promega)
was added at the ®nal step and incubated for 30 min at
22°C. Color was developed using ABTS (Sigma) substrate,
and the absorbance was measured at 405 nm. Recombinant
mouse Ccl7 protein (R&D Systems) was used as standard for
quanti®cation.
E-selectin and VCAM-1 surface expression on MHEC was
quanti®ed as previously described (30). Brie¯y, MHEC were
seeded in 96-well plates and culture until con¯uence. Cells
were then washed in PBS and ®xed in 0.2% glutaraldehyde
(Sigma) for 40 min at room temperature. Plates were saturated
overnight in PBS containing 1% BSA. After three washes, the
cells were incubated with rat anti-mouse E-selectin or VCAM-
1 monoclonal antibodies at 37°C for 1 h. After three more
washes, the cells were incubated with horseradish peroxidase-
conjugated goat anti-rat IgG for 1 h at 37°C. The reaction was
developed using ABTS substrate, and the absorbance was
measured at 405 nm.
Adhesion assay
For cell adhesion, Concanavalin A-stimulated murine spleno-
cytes cultured in the presence of 500 U/ml of IL-2 (gift of
Hoffmann-La Roche, Nutley, NJ) for 3 days were labeled with
the ¯uorescent dye BCECF-AM (Molecular probes, The
Netherlands), and added in RPMI medium to a monolayer of
resting or TNF-a-activated endothelial cells from both
genotypes. After incubation for 20 min at 37°C, unbound
cells were removed by three washes with RPMI medium, and
adhered cells were quanti®ed using a ¯uorescence analyzer
(BMG, Durham, NC). In all experiments a control plate using
titrated numbers of labeled splenocytes was set up to establish
a linear relationship between cell number and the mean
¯uorescence.
RESULTS
Transcriptional programs in PARP-1+/+ versus PARP-
1±/± endothelial cells in response to TNF-a
The gene expression pro®les induced by TNF-a in primary
MHEC derived from PARP-1-wild-type and PARP-1-de®-
cient mice were analyzed using oligonucleotide microarray
technology. Primary cells (passage 3) grown under identical
conditions to ~80% con¯uency were stimulated with 20 ng/ml
recombinant mouse TNF-a for 2 h. Total RNA prepared from
resting or TNF-a-stimulated cells were further puri®ed, and
labeled cRNA was prepared for DNA microarray analyses
using Affymetrix oligonucleotide chips (murine genome
U74A) containing probes for 12 488 known mouse genes or
ESTs. Only those changes in RNA abundance that were
reproducible in independent experiments using different
batches of endothelial cells were considered. Genes that
appeared to be differentially expressed by a factor >2-fold
between untreated and TNF-a-stimulated cells are represented
in Figure 1, classi®ed into a number of functional categories.
Those include chemokines, adhesion molecules, growth
factors, cell signaling molecules, transcription factors, apop-
tosis related molecules and metabolic mediators. In addition to
these differentially expressed known full-length genes, we
also identi®ed a number of differentially expressed ESTs
(Fig. 1). The identi®cation of full cDNA encoding for these
unknown genes as well as their biological relevance will be
addressed in additional studies. TNF-a modulated a signi®-
cant number of early-response genes (0.34%) in PARP-1-
expressing endothelial cells, up-regulating 40 and concomi-
tantly down-regulating three transcripts, while in PARP-1-
de®cient endothelial cells 39 of genes (0.32%) were modu-
lated, up-regulating 36 genes and down-regulating three
transcripts (Fig. 1). Expression pattern of these genes was
similar under basic conditions in both cell types. Expression of
28 early-response genes to TNF-a was similar in PARP-1+/+
and PARP-1±/± endothelial cells (fold change <1.5). However,
we found 18 early-response genes to TNF-a whose expression
seems to be PARP-1-dependent (Table 2). To validate the
array data, we also evaluated expression of several of these
genes by quantitative real-time PCR. Although there were
differences in the fold-change absolute values detected by the
two methods, in every case, PCR results correlated well with
Table 2. Silencing and enhancing transcription of early-response genes to
TNF-a by PARP-1 in MHECsa
Positive regulation Negative regulation
Gene Fold change Gene Fold change
Ccl5 1.8 Cx3cl1 1.7
Cxcl5 2.3 Cxcl10 4.4
Ccl7 2.8 Csf2 1.9
E-selectin 1.5 Gem 6.2
Itga5 2.5 Lyl1 2.9
Gadd45b 4.7 Irg1 1.6
Slfn2 3.6
Areg 2.4
Rgs 16 2.7
Ifrd1 1.8
EST (AA420407) 3.3
Zfp46 7.8
aGenes were classi®ed as PARP-1-dependent genes when their expression in
response to TNF-a was changed by a factor of at least 1.5 between PARP-
1+/+ and PARP-1±/± cells in the microarrays analysis. Fold change expressed
the ratio of gene expression in PARP-1+/+ over PARP-1±/± cells (positive
regulation column) or the ratio of gene expression in PARP-1±/± over
PARP-1+/+ cells (negative regulation column).
Figure 1. Differential gene expression patterns in PARP-1+/+ and PARP-1±/± MHECs in response to TNF-a. Gene expression pro®les were generated using an
Affymetrix U74Av2 microarray and analyzed using GeneChip software. The x-axis represents fold-change of activated versus resting cells for both PARP-1+/+
(white bars) and PARP-1±/± (black bars) cells. TNF-a-responsive genes have been clustered according to function, and the corresponding GenBank accession
numbers are indicated. Genes with no change >2-fold between untreated and TNF-a-stimulated in PARP-1+/+ cells (Cxcl10, Gem and Zfp46) or in PARP-1±/±
cells (Rgs16, Itga5, Areg, Slfn2, Gadd45b, Lyl1 and AA420407) are not indicated. Results represent the mean value of two independent experiments using
different batches of heart endothelial cells.
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the differential gene expression data produced using
Affymetrix GeneChips (Fig. 2).
Role of PARP-1 in endothelial cells gene expression of
molecules involved in in¯ammation after TNF-a
treatment
A subset of genes (~40%) with altered expression by MHEC in
response to TNF-a encode for chemokines, growth factors and
adhesion molecules which are major regulators of mono-
nuclear and polymorphonuclear cell traf®cking across the
endothelium in various forms of in¯ammation. All genes in
the chemokines group were upregulated (or unmodi®ed) after
stimulation in both PARP-1-wild-type and PARP-1-de®cient
endothelial cells (Fig. 1). Transcription of Ccl5, Ccl7 and
Cxcl5 genes is markedly induced in PARP-1+/+ endothelial
cells in response to TNF-a but their upregulation was
inhibited in PARP-1±/± endothelial cells (Fig. 1). However,
macrophage in¯ammatory protein 2 (MIP-2 or Cxcl2), Cxcl1
and IL6 genes were similarly up-regulated in both cell types.
Cx3cl1 chemokine gene was slightly up-regulated in PARP-
1+/+ and higher in PARP-1±/±, while Cxcl10 was up-regulated
only in PARP-1-de®cient cells in response to TNF-a. Genes
included in the growth factors group were also upregulated
after stimulation in PARP-1-wild-type cells, while only one
was up-regulated in PARP-1-de®cient endothelial cells
(Fig. 1). The up-regulation of macrophage colony stimulating
factor 2 gene (Csf2) in PARP-1±/± cells was 2-fold higher than
observed in wild-type cells (Fig. 1). Differences in the
expression of several genes included in both functional groups
were veri®ed by quantitative real-time PCR (Fig. 2).
A fundamental and early event in in¯ammation is adhesion
of leukocytes to the endothelium. This is mediated by
binding of leukocytes to endothelial cells adhesion molecules
such as E-selectin (Sele), vascular cell adhesion molecule-1
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1).
Expression of E-selectin gene was highly up-regulated in
PARP-1+/+ cells and to a lesser extent in PARP-1±/± cells in
response to 2 h TNF-a treatment. On the other hand, similar
level of up-regulation was found for ICAM-1, VCAM-1 and
Selp genes in both PARP-1-wild-type and PARP-1-de®cient
endothelial cells at this early stage of activation. The
®bronectin 2 receptor gene (Itga5) was up-regulated in
Figure 3. Cell surface expression of E-selectin (A) and VCAM-1 (B) in
both PARP-1+/+ (white bars) and PARP-1±/± (black bars) endothelial cells in
response to 6 h TNF-a treatment (20 ng/ml). ELISAs were performed on
®xed cells. Absorbencies measured at 405 nm are plotted in the y-axis. A
representative of three experiments is shown. (C) Cell adhesion of activated
murine splenocytes to TNF-a-activated PARP-1+/+ (white bars) and PARP-
1±/± (black bars) endothelial cells. Error bars indicate standard error.
Figure 2. Real-time PCR of select genes identi®ed as differentially ex-
pressed by GeneChip analysis. Samples were normalized according to actin
expression level. The x-axis represents fold-change of activated versus rest-
ing cells for both PARP-1+/+ (white bars) and PARP-1±/± (black bars) cells.
Results represent the mean value of two independent experiments using dif-
ferent batches of heart endothelial cells.
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PARP-1+/+ but not in PARP-1±/± cells (Fig. 1). Expression of
several adhesion molecules genes (E-selectin and VCAM-1)
in response to TNF-a was also veri®ed at protein level by
ELISA in both cell types (Fig. 3A and B). Moreover,
lymphocyte adhesion to a monolayer of TNF-a-activated
endothelial cells was higher in PARP-1+/+ than PARP-1±/±
endothelial cells (Fig. 3C).
Silencing and enhancing transcription of NF-kB-target
genes by PARP-1 in MHECs
NF-kB pathway plays a critical role in the response to TNF-a
by endothelial cells (31). TNF-a signaling led to proteolytic
degradation of IkBa by the 26S proteasome complex, which is
necessary for NF-kB nuclear translocation and therefore NF-
kB-dependent transcription activation (32). The transcrip-
tional status of NF-kB was examined in transiently transfected
heart endothelial cells of both PARP-1+/+ and PARP-1±/±
genotypes stimulated with TNF-a (for 6 h) using a luciferase
reporter plasmid under the control of a 3 3 kB consensus site
from the HIV enhancer (29). Our results show that NF-kB-
dependent transcriptional activation was partially inhibited in
PARP-1-de®cient MHEC in response to TNF-a compared to
PARP-1+/+ cells (Fig. 4A). To demonstrate the speci®city of
TNF-a, we performed a control experiment using the pGL3-
control vector, a basic luciferase reporter vector under the
control of a SV40 promoter (Fig. 4B). To study a possible
correlation between NF-kB target genes and a positive or a
negative effect of PARP-1 in their regulation, we next
examined the effect of proteasome inhibition on expression
of several genes by TNF-a-stimulated MHEC by real-time
PCR. IkBa degradation as a prerequisite for NF-kB activation
could be blocked by incubation of the cells with proteasome
inhibitors such as MG132 (32,33). As expected, pre-incuba-
tion of MHEC with MG132 inhibited the NF-kB-dependent
transcriptional activation induced by TNF-a in both PARP-
1+/+ and PARP-1±/± cells (Fig. 4A). Preincubation of MHEC
with MG132 blocked the TNF-a-mediated up-regulation of
different genes, suggesting to us that NF-kB is critical for the
transcription of these genes by MHEC (Fig. 5). Although NF-
kB-dependent transcriptional activation is hampered in
PARP-1±/± MHEC we found examples of NF-kB-target
genes (Figs 5 and 6) whose expression is silencing by
PARP-1 (Cxcl10, Csf2) (Figs 1 and 6A and Table 2) and NF-
kB-target genes whose expression is enhancing by PARP-1
(Ccl7, Cxcl5) (Figs 1 and 6B and Table 2).
Expression of MIP-2 by MHEC in response to TNF-a was
similar in PARP-1+/+ and PARP-1±/± cells (Figs 1 and 6C). The
up-regulation of this gene in MHECs seems to be NF-kB-
independent as their up-regulation was not inhibited by using
the proteasome inhibitor MG132 at both mRNA and protein
level (Figs 5 and 6C). The results obtained for the MIP-2 gene
in our MHEC con®rms a recent observation of Hipp et al. (32),
which has demonstrated high expression of human IL-8 (the
human homolog to mouse MIP-2) (34) by human arterial
endothelial cells despite complete suppression of NF-kB
activity by proteasome inhibition.
DISCUSSION
In the present study, we used a large-scale gene expression
analysis to study the role played by PARP-1 in MHECs early
Figure 4. Defective NF-kB-dependent transcriptional activation on TNF-a-
stimulated PARP-1±/± heart endothelial cells. Cells were transiently co-trans-
fected with a ®re¯y luciferase reporter plasmid under the control of a 3 3
kB promoter element (A) or the pGL3-control vector, a basic ®re¯y lucifer-
ase reporter vector under the control of a SV40 promoter (B) and the
Renilla luciferase expression vector pRLCMV. After 72 h, cells were pre-
treated with MG-132 for 1 h and subsequently treated for 6 h with TNF-a
(20 ng/ml) as indicated. Results were normalized as indicated in Materials
and Methods. The ratio obtained for untreated cells was arbitrarily set to 1.
A representative of three experiments is shown. Error bars indicate standard
error.
Figure 5. Effect of proteasome inhibition on gene expression of selected
genes, (A) PARP-1-independent gene, (B) genes negatively regulated by
PARP-1 and (C) genes positively regulated by PARP-1, in response to
TNF-a. MHECs were pre-treated for 1 h with MG-132 and then exposed to
TNF-a for 2 h. Expression analysis was carried out by real-time PCR as de-
scribed in Figure 2. The y-axis represents fold-change of activated versus
resting PARP-1+/+ cells in the absence of MG132 (white bars) or after pre-
incubation with MG132 (black bars).
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gene expression in reponse to TNF-a. Previously, it has been
demonstrated that TNF-a-induced activation of the stress/
in¯ammation transcription factors NF-kB, AP-1, SP-1, Oct-1,
YY-1 and Stat-1 in macrophages, ®broblasts and glia cells
requires PARP-1 (23,26). Our microarray analysis revealed
early TNF-a-response genes in MHEC with various biological
functions and include chemokines, growth factors, cell
signaling molecules, adhesion molecules, transcription fac-
tors, apoptotic molecules and metabolic mediators. Eighteen
of these genes (40%) seem to be PARP-1-dependent genes,
whereas expression of the other 28 genes did not show
differences between PARP-1+/+ and PARP-1±/± MHEC in
response to TNF-a (PARP-1-independent genes) at this early
time point after activation.
Many TNF-a-induced genes by MHEC represent potential
mediators of the in¯ammatory response. Moreover, a number
of them have been previously characterized as NF-kB targets,
including MIP-2, Ccl5, Cxcl1, Cxcl10, IL-6, E-selectin, Csf
(35) and Gadd45b (36). Recent reports have shown that NF-
kB activation depends on PARP-1, suggesting a critical role of
this protein as an essential transcriptional coactivator for kB-
dependent gene expression (10,23,25). Our results showed that
NF-kB-dependent transcriptional activation is hampered in
PARP-1±/± MHEC in response to TNF-a. Similar results have
been previously reported by Garcia-Soriano et al. after high-
glucose stimulation of PARP-1+/+ and PARP-1±/± endothelial
cells (10) and by Oliver et al. (23) in TNF-a-activated
®broblast from both genotypes. Likewise, we have also found
that the upregulation of the majority of genes involved in the
in¯ammatory response after TNF-a treatment seems to be
PARP-1-dependent genes. Furthermore, expression of some of
these genes is inhibited in the absence of PARP-1, con®rming
the results of previous workers that PARP-1 is an important
molecule in the regulation of in¯ammation (18,37). However,
a few genes included in this functional group, such as Cxcl10
and Csf2, are higher responders to TNF-a in the absence of
PARP-1. A similar effect was observed in other genes
belonging to different functional categories such as Gem
and Irg1 genes. In fact, PARP-1±/± mice do not show the same
phenotype as mice lacking NF-kB family members (38,39)
indicated that only a subset of kB-dependent genes are
modulated by PARP-1 and that the requirement of PARP-1 for
kB-dependent gene expression may be dependent on the tissue
and development stage-speci®c expression of PARP-1. On the
other hand, using chromatin immunoprecipitation, Saccani
et al. have shown that after an acute stimulation two distinct
waves of NF-kB recruitment to target promoters occur: a fast
recruitment to constitutively and immediately accessible
promoters and a late recruitment to promoters requiring
stimulus-dependent modi®cations in chromatin structure to
make NF-kB sites accessible. This new regulatory level
implies a mechanism of speci®city in NF-kB-dependent
transcriptional responses based on the ability of individual
stimuli to make late recruitment promoters accessible to NF-
kB before its rapid extrusion from the nucleus (40). PARP-1
could be involved in the second wave of NF-kB dependent
transcription through its ability to modify chromatin-associ-
ated proteins.
Many of pathways in response to TNF-a have proved to be
cell type-speci®c, requiring that observations made in other
cell types be con®rmed or ruled out in endothelial cells (41).
Thus, we next studied whether these genes are indeed NF-kB
targets in MHECs. TNF-a signaling involved IkBa degrad-
ation and subsequent NF-kB nuclear translocation. IkBa
degradation could be blocked by incubation of the cells with
proteasome inhibitors such as MG-132 (32,33). Our data
showed that pre-incubation of MHEC with this inhibitor
dramatically blocks the NF-kB-dependent transcriptional
activity. By using this approach, we found that with the
exception of MIP-2, expression of all genes analyzed was
affected by proteasome inhibition, suggesting that they are
NF-kB targets in MHECs. Although NF-kB-dependent tran-
scriptional activity is hampered in PARP-1±/± MHEC, our
results show that PARP-1 is regulating the expression of NF-
kB-dependent genes both in a positive and a negative fashion,
Figure 6. TNF-a-induced chemokine production in both PARP-1+/+ (white
bars) and PARP-1±/± (black bars) endothelial cells. MHECs were stimulated
for 24 h (A and C) or 6 h (B) with 20 ng/ml TNF-a, in the presence or ab-
sence of MG132. The levels of Cxcl10 (A), Ccl7 (B) and MIP-2 (C) chemo-
kines were measured by ELISA. A representative of three experiments is
shown. Error bars indicate standard error.
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with the ®nal effects depending on the gene. This result
suggests different regulatory mechanisms controlling the
transcription of these genes. In fact, PARP-1 might modulate
gene expression through different mechanisms: (i) physical
interactions with other proteins, especially transcription
factors; (ii) direct binding to the gene-regulating sequences;
and (iii) transient post-translational modi®cations of nuclear
proteins by poly(ADP-ribosyl)ation. Recently, Soldatenkov
et al. have demonstrated transcriptional repression of PARP
gene expression by binding of PARP to its own promoter
sequences (42). PARP has also been shown to bind the IL-6/
glucocorticoid-responsive element of Reg gene, forming the
active transcriptional DNA/protein complex for Reg gene
expression (43). Thus, PARP-1 appears to have dual functions
in the regulation of transcription working as a silencing or
enhancing transcription factor.
Expression of MIP-2 at both mRNA and protein levels was
not blocked by proteasome inhibitor treatment suggesting that
its expression in MHEC was NF-kB independent. Our results
on MIP-2 gene expression by MHEC con®rm the data
obtained by Hipp et al. (32) on the expression of human IL-
8, the human homolog to murine MIP-2 (34), suggesting that
NF-kB is dispensable for MIP-2 activation in murine
endothelial cells as it is for IL-8 expression in human
endothelial cells. Recently, HaskoÂ et al. (37) have reported
that the production of MIP-2 in response to lipopolysaccharide
was abolished in PARP-1±/± ®broblasts. In here, we found
similar expression in both cell types. This difference could be
attributed to the fact that the factors involved in MIP-2
transcription regulation are different in ®broblasts and
endothelial cells. In fact, we found that proteasome inhibition
increases MIP-2 expression at both RNA and protein levels in
MHEC. Hipp et al. (32) have also demonstrated that
proteasome inhibition induced IL-8 expression in endothelial
cells, and these inhibitors suppressed NF-kB but increased
AP-1 activity.
In summary, by using DNA microarray technology, we
have identi®ed a set of genes in MHEC whose early
expression in response to TNF-a is modulated by PARP-1,
but with the ®nal effect depending on the gene. Individual
studies in each of these genes are now necessary to clarify the
intrinsic mechanisms by which PARP-1 is controlling tran-
scription and thereby ®nding out different therapeutic
approaches involving PARP-1.
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